Claims for Patent: 5,981,725

Summary for Patent: 5,981,725

Title:	Structural alterations of the EGF receptor gene in human tumors
Abstract:	Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.
Inventor(s):	Vogelstein; Bert (Baltimore, MD), Bigner; Darell (Mebane, NC)
Assignee:	The Johns Hopkins Univiersity (Baltimore, MD) Duke University (Durham, NC)
Application Number:	08/479,808
Patent Claims:	1. An intron-free DNA molecule comprising a DNA sequence which encodes a type II EGFR mutant peptide having the sequence Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-Val-Thr. 2. An intron-free DNA molecule encoding a type II EFGR mutant peptide, said DNA molecule comprising a DNA sequence consisting of CTG-GAG-GAA-AAG-AAA-GGT-AAT-TAT-GTG-GTG-ACA. 3. A vector containing a DNA molecule of claim 1. 4. A vector containing a DNA molecule of claim 2. 5. A transformed cell containing the vector of claim 3. 6. A transformed cell containing the vector of claim 4. 7. The DNA molecule of claim 1 wherein the DNA molecule encodes an EGFR type II peptide of less than 50 amino acids. 8. The intron-free DNA molecule of claim 1 wherein the DNA sequence encodes a type II EGFR mutant peptide comprising the sequence Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-Val-Thr-Asp-His-Cys. 9. A nucleotide probe comprising a sequence encoding a type II EGFR mutant peptide, said sequence consisting of CTG-GAG-GAA-AAG-AAA-GGT-AAT-TAT-GTG-GTG-ACA or the complement thereof. 10. The nucleotide probe of claim 9 which comprises less than 50 codons of an EGFR type II peptide. 11. A kit for detecting a type II EGFR mutation comprising: a pair of nucleic acid primers for amplification of a deletion junction found in RNA of cells having a type II EGFR mutation, said pair of primers consisting of a first primer which comprises a sequence of contiguous wild-type EGFR nucleotides which are 5' to said deletion junction and a second primer which comprises a sequence of contiguous wild-type EGFR nucleotides which are 3' to said deletion junction; and a nucleotide probe comprising a sequence encoding a type II EGFR mutant peptide, said sequence consisting of CTG-GAG-GAA-AAG-AAA-GGT-AAT-TAT-GTG-GTG-ACA or the complement thereof. 12. The kit of claim 11 wherein the nucleotide probe comprises less than 50 codons of an EGFR type II peptide.

Details for Patent 5,981,725

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-11-09